New combo aims to tame deadly leukemia in High-Risk patients
NCT ID NCT07187505
First seen Sep 30, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This study tests whether adding venetoclax to standard treatment (ATRA and arsenic trioxide) can improve survival for people with a rare blood cancer called acute promyelocytic leukemia (APL) who have dangerously high white blood cell counts. About 28 newly diagnosed patients will receive the combination therapy. The main goal is to see if it lowers the risk of early death within the first 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road
Hefei, Anhui, 230022, China
Conditions
Explore the condition pages connected to this study.